Loading the map…
Private limited company registered in Leeds, classed under “Research and experimental development on biotechnology”.
Headline figures
FY to Dec 2024 · Company only
Turnover
For subscribers
Profit after tax
—
Not found in sources
Net assets
For subscribers
Cash
For subscribers
Employees
For subscribers
Retained reserves
For subscribers
What the numbers say
3 findings from the figures, in plain English
Written by rules from the figures on this page. Not a forecast or a credit opinion.
History
| £ | 2022 | 2023 | 2024 |
|---|---|---|---|
| Profit after tax | — | ||
| Turnover | |||
| Net assets | |||
| Cash | |||
| Employees | |||
| Retained reserves |
Every figure for all 3 years
“—” means we did not find the figure in a source; it is never filled with an estimate.
Balance sheet and ratios
From the filed balance sheets · £
| Balance sheet | 2022 | 2023 | 2024 |
|---|---|---|---|
| Fixed assets | |||
| Current assets | |||
| of which debtors | |||
| of which cash | |||
| Creditors due within a year | |||
| Net current assets | |||
| Creditors due after a year | |||
| Net assets | |||
| Ratios | |||
| Current ratioCurrent assets for every £1 owed within a year | |||
| Cash ratioCash for every £1 owed within a year | |||
| Creditors to assetsEverything owed to creditors as a share of fixed plus current assets | |||
| Turnover per employeeTurnover divided by average staff | |||
8 balance-sheet lines and 4 ratios, every year
A ratio appears only for years where every line it needs was filed. Lines are as tagged in the accounts; nothing is added up or estimated.
Timeline
Checked 2026-10-23
- DirectorsAppointment of Gregory Lee Weaver as a director on 24 July 2026
- OwnershipCessation of Vipin Garg as a person with significant control on 4 June 2026
- DirectorsTermination of appointment of Vipin Garg as a director on 4 June 2026
- DirectorsAppointment of Altimmune, Inc. as a director on 4 June 2026
- AccountsAmended accounts for a small company made up to 31 December 2024
- AccountsTotal exemption full accounts made up to 31 December 2024
- AccountsAmended accounts for a small company made up to 31 December 2023
- AccountsTotal exemption full accounts made up to 31 December 2023
- AccountsAccounts for a small company made up to 31 December 2022
- DirectorsDirector's details changed for President Vipin Garg on 30 May 2023
- OwnershipChange of details for President Vipin Garg as a person with significant control on 30 May 2023
- AccountsAccounts for a small company made up to 31 December 2021
27 earlier
- OwnershipSecond filing for the notification of Vipin Garg as a person with significant control
- DirectorsSecond filing for the appointment of President Vipin Garg as a director (and 1 more like it since 17 May 2022)
- AccountsAccounts for a small company made up to 31 December 2020
- OwnershipNotification of Altimmune, Inc. as a person with significant control on 13 May 2021
- AccountsGroup of companies' accounts made up to 31 December 2019
- AccountsGroup of companies' accounts made up to 31 December 2018
- OwnershipNotification of Vipin Garg as a person with significant control on 30 November 2018
- DirectorsAppointment of Vipin Garg as a director on 30 November 2018
- OwnershipCessation of William James Enright as a person with significant control on 30 November 2018
- DirectorsTermination of appointment of William James Enright as a director on 30 November 2018
- AddressRegistered office address changed from London Bioscience Innovation Centre, 2 Royal College Street London NW1 0NH to Central Square 5th Floor 29 Wellington Street Leeds LS1 4DL …
- AccountsGroup of companies' accounts made up to 31 December 2017
- DirectorsTermination of appointment of Elizabeth Adkins Czerepak as a director on 8 May 2018
- OwnershipCessation of Elizabeth Adkins Czerepak as a person with significant control on 8 May 2018
- OwnershipNotification of Elizabeth Adkins Czerepak as a person with significant control on 6 June 2017
- OwnershipNotification of William James Enright as a person with significant control on 6 June 2017
- OwnershipNotification of Elizabeth Adkins Czerepak as a person with significant control on 18 July 2017
- DirectorsAppointment of Mrs. Elizabeth Adkins Czerepak as a director on 6 June 2017
- DirectorsTermination of appointment of Klaus Otto Schäfer as a director on 6 June 2017
- DirectorsTermination of appointment of Philippe Jacques Michel Pouletty as a director on 6 June 2017
- DirectorsTermination of appointment of David Drutz as a director on 6 June 2017
- DirectorsTermination of appointment of Philip Lawton Hodges as a director on 6 June 2017
- DirectorsTermination of appointment of Marten Steen as a director on 6 June 2017
- DirectorsTermination of appointment of Christine Brennan as a director on 6 June 2017
- AccountsGroup of companies' accounts made up to 31 December 2016
- AccountsFull accounts made up to 31 December 2015
- DirectorsAppointment of Dr. Christine Brennan as a director on 8 September 2016
- Ownership
From the Companies House filing history. Routine confirmation statements are left out, and a run of the same filing is shown once.
Questions people ask
›What does Altimmune UK do?
Private limited company registered in Leeds, classed under “Research and experimental development on biotechnology”.
›How much turnover does Altimmune UK make?
Answered in the full report
›Is Altimmune UK profitable?
We haven't found a profit figure in Altimmune UK's latest filed accounts.
›How many people work at Altimmune UK?
Answered in the full report
›Who runs and owns Altimmune UK?
Its directors are Gregory Lee Weaver, Altimmune, Inc.. Its owners are shown to subscribers.
›Where is Altimmune UK based?
Its registered office is Central Square 5th Floor, 29 Wellington Street, Leeds, LS1 4DL, in Leeds.
›When was Altimmune UK founded?
Altimmune UK Limited was incorporated on 5 October 1992.
›Is Altimmune UK still trading?
The register lists Altimmune UK Limited as active.